Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Gastrointestinal Stromal Tumor

Terminated

3

Start Date 04/01/2009

Age of Trial (yrs) 15.7

Gleevec-resistant

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

CAMN107DBR01

Novartis

Novartis US: 1-800-340-6843

Randomized

Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg

Arm 1 800mg per day Nilotinib experimental
Arm 2: 800mg per day Imatinib active comparator